US Patent 8785501 Anti-cancer tamoxifen-melatonin hybrid ligand
Patent 8785501 was granted and assigned to Duquesne University on July, 2014 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 8785501 Anti-cancer tamoxifen-melatonin hybrid ligand
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.